Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO

Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO

2024.03.05
Amidst the waves and scenic beauty, from January 26th to 28th, the "China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. Renowned experts and scholars from both domestic and international arenas gathered to share and exchange important research findings in the fields of leukemia, lymphoma, and myeloma over the past year. They also delved into in-depth discussions on hot topics in diagnosis and treatment. Oncology Frontier - Hematology Frontier had the privilege of interviewing Professor Jun Ma, the executive chairman of this conference and director of the Harbin Institute of Hematological Tumors. He elaborated on the highlights and exciting aspects of the conference, shared insights on the significance of establishing standardized lymphoma diagnosis and treatment centers, and highlighted the working priorities of the 2024 CSCO Leukemia and Lymphoma Expert Committees.
Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

2024.03.05
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. At the conference, experts of all ages from both domestic and international arenas engaged in discussions and exchanges on the latest developments and hot topics in lymphoma diagnosis and treatment. "Oncology Frontier - Hematology Frontier" had the privilege to interview Professor Aichun Liu, Director of the Department of Hematology and Lymphoma at Harbin Medical University Cancer Hospital, regarding his perspectives and opinions on the overall treatment strategy for relapsed/refractory B-cell lymphoma, as well as sharing his team's research plans and management experiences in lymphoma.
Professor Hui Wei: Mutual learning and progress, new treatment strategies and future directions in the field of leukemia | 2024 CSCO

Professor Hui Wei: Mutual learning and progress, new treatment strategies and future directions in the field of leukemia | 2024 CSCO

2024.03.05
With the rapid development of targeted therapy and immunotherapy, the field of leukemia treatment has undergone revolutionary changes. At the recently held "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference," domestic and international experts, both senior and junior, actively exchanged ideas and engaged in lively discussions on the latest developments and hot topics in leukemia diagnosis and treatment. During the conference, Oncology Frontier - Hematology Frontier specially invited Professor Hui Wei, one of the co-chairs of the leukemia youth session at this conference and director of the Leukemia Diagnosis and Treatment Center of the Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Blood Disease Hospital), to introduce the highlights of the leukemia field at this conference. Professor Wei also provided insights into the future treatment directions for ETP Acute Leukemia (ETP-ALL) and analyzed related challenges in CAR-T cell therapy.
Professor DeHui Zou : Progress and Considerations in CAR-T Therapy for Diffuse Large B-Cell Lymphoma | 2024 CSCO Hematology Academic Conference

Professor DeHui Zou : Progress and Considerations in CAR-T Therapy for Diffuse Large B-Cell Lymphoma | 2024 CSCO Hematology Academic Conference

2024.03.05
With unceasing exploration, the grand event took place as scheduled. From January 26 to 28, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Committee Work Meeting and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma" was grandly held in the beautiful city of Haikou. Renowned experts and scholars from home and abroad gathered to share and exchange on the latest advancements and hot topics in the field of hematologic malignancies. At the conference, Professor DeHui Zou from the Lymphoma Diagnosis and Treatment Center of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented on "Progress and Considerations in CAR-T Therapy for B-Cell Lymphomas," sharing the latest research progress in the efficacy, therapeutic status, challenges faced, and optimization strategies for CAR-T treatment of Diffuse Large B-Cell Lymphoma (DLBCL). The following is a special summary.
2024 CASH丨Professor Jinghui Zhang：Monitoring clonal hematopoiesis in pediatric patients helps improve long-term prognosis

2024 CASH丨Professor Jinghui Zhang：Monitoring clonal hematopoiesis in pediatric patients helps improve long-term prognosis

2024.03.04
Clonal hematopoiesis typically refers to the proliferation of hematopoietic stem cells due to genetic mutations, which is also the basis for various hematologic diseases; monitoring clonal hematopoiesis helps in early detection of hematologic malignancies. At the Fourth China Hematology Development Conference (CASH) held recently, Professor Jinghui Zhang from St. Jude Children's Research Hospital shared a report titled "Treatment-Related Clonal Hematopoiesis in Pediatric Cancer Survivors." Following the conference, "Oncology Frontier - Hematology Frontier" invited Professor Jinghui Zhang to delve deeply into the treatment-related causes, monitoring value, and long-term effects of clonal hematopoiesis.
2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL

2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL

2024.03.04
The Fourth China Hematology Development Conference was held in Tianjin from January 5 to 7, 2024. Themed "Broad Hematology, Public Health, and Overall Well-being," the conference centered around the core development directions of hematology, as well as major disciplinary issues faced in basic hematology research, translation, and clinical diagnosis and treatment in the new era. It featured discussions and in-depth explorations of hot topics and frontiers, aiming to promote the construction and vigorous development of the hematology field. On this occasion, Professor Ying Wang , Director of the Comprehensive Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, was interviewed to share the progress and breakthroughs in immunotherapy within the field of Acute Lymphoblastic Leukemia (ALL).